drugset / Trial / NCT05244798
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
Phase 3
Not yet recruiting
420 enrolled
Sichuan Cancer Hospital and Research Institute
Anhui Provincial Hospital · collabAnyang Tumor Hospital · collabGeneCast Biotechnology Co., Ltd. · collabHebei Medical University Fourth Hospital · collabInnovent Biologics (Suzhou) Co. Ltd. · collabPeking University Cancer Hospital & Institute · collabShantou Central Hospital · collabThe First Affiliated Hospital with Nanjing Medical University · collabTianjin Medical University Cancer Institute and Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Comparative analysis of patients with resectable locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy combined sintilimab versus neoadjuvant chemoradiotherapy.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |